Brokerages Anticipate Lannett Co Inc (LCI) Will Announce Quarterly Sales of $153.21 Million
Equities analysts predict that Lannett Co Inc (NYSE:LCI) will announce $153.21 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Lannett Co’s earnings. The highest sales estimate is $154.46 million and the lowest is $151.10 million. Lannett Co reported sales of $161.56 million in the same quarter last year, which indicates a negative year-over-year growth rate of 5.2%. The company is expected to report its next earnings results on Thursday, November 2nd.
On average, analysts expect that Lannett Co will report full-year sales of $153.21 million for the current financial year, with estimates ranging from $655.10 million to $693.00 million. For the next financial year, analysts anticipate that the company will report sales of $673.54 million per share, with estimates ranging from $627.53 million to $694.80 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Lannett Co.
Lannett Co (NYSE:LCI) last issued its quarterly earnings data on Wednesday, August 23rd. The company reported $0.40 earnings per share for the quarter, meeting the consensus estimate of $0.40. The firm had revenue of $139.10 million for the quarter, compared to analyst estimates of $139.01 million. Lannett Co had a negative net margin of 0.09% and a positive return on equity of 19.80%. The company’s revenue for the quarter was down 17.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.73 earnings per share.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/13/brokerages-anticipate-lannett-co-inc-lci-will-announce-quarterly-sales-of-153-21-million.html.
Several institutional investors have recently made changes to their positions in the company. Arizona State Retirement System raised its stake in shares of Lannett Co by 0.7% during the 2nd quarter. Arizona State Retirement System now owns 15,362 shares of the company’s stock worth $313,000 after purchasing an additional 100 shares in the last quarter. CS Mckee LP raised its stake in shares of Lannett Co by 0.6% during the 2nd quarter. CS Mckee LP now owns 35,400 shares of the company’s stock worth $722,000 after purchasing an additional 200 shares in the last quarter. Texas Permanent School Fund raised its stake in shares of Lannett Co by 1.0% during the 2nd quarter. Texas Permanent School Fund now owns 21,474 shares of the company’s stock worth $438,000 after purchasing an additional 203 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Lannett Co by 0.4% during the 2nd quarter. Rhumbline Advisers now owns 61,600 shares of the company’s stock worth $1,257,000 after purchasing an additional 244 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Lannett Co by 1.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,366 shares of the company’s stock worth $456,000 after purchasing an additional 297 shares in the last quarter. Institutional investors own 87.92% of the company’s stock.
About Lannett Co
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.